Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals; Sanofi

    • Most Recent Events

    • 27 Sep 2022 Results comparing dupilumab pharmacokinetics from studies (POC; NCT02379052 & LIBERTY EoE TREETstudy (NCT03633617)) to previous dupilumab trials in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
    • 27 Oct 2021 Results assessing relationship esophageal intraepithelial eosinophil count (eos/hpf) and EREFS total score, inflammation and remodeling subscores, and individual components scores in patients with EoE receiving placebo in the phase 2 POC study and part A of the phase 3 LIBERTY TREET study, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
    • 27 Oct 2021 Results assessing Histology Scoring System (HSS) components correlate with inflammatory or remodeling EREFS components in EoE patients receiving placebo in 2 trials; 12-week phase 2 proof-of-concept (POC; NCT02379052) in adults and 24-week part A of the 3-part, phase 3 TREET (P3PA; NCT03633617) in adults and adolescents, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top